Fig_S1 – Supplemental material for A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

Merz, Valeria; Zecchetto, Camilla; Simionato, Francesca; Cavaliere, Alessandro; Casalino, Simona; Pavarana, Michele; Giacopuzzi, Simone; Bencivenga, Maria; Tomezzoli, Anna; Santoro, Raffaela; Fedele, Vita; Contarelli, Serena; Rossi, Irene; Giacomazzi, Serena; Pasquato, Martina; Piazzola, Cristiana; Milleri, Stefano; de Manzoni, Giovanni; Melisi, Davide

doi:10.25384/SAGE.12630895.v1

Fig_S1.pdf (116.18 kB)

Fig_S1 – Supplemental material for A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

journal contribution

posted on 2020-07-09, 12:07 authored by Valeria Merz, Camilla Zecchetto, Francesca Simionato, Alessandro Cavaliere, Simona Casalino, Michele Pavarana, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Raffaela Santoro, Vita Fedele, Serena Contarelli, Irene Rossi, Serena Giacomazzi, Martina Pasquato, Cristiana Piazzola, Stefano Milleri, Giovanni de Manzoni, Davide Melisi

Supplemental material, Fig_S1 for A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial by Valeria Merz, Camilla Zecchetto, Francesca Simionato, Alessandro Cavaliere, Simona Casalino, Michele Pavarana, Simone Giacopuzzi, Maria Bencivenga, Anna Tomezzoli, Raffaela Santoro, Vita Fedele, Serena Contarelli, Irene Rossi, Serena Giacomazzi, Martina Pasquato, Cristiana Piazzola, Stefano Milleri, Giovanni de Manzoni and Davide Melisi in Therapeutic Advances in Medical Oncology